Human basic fibroblast growth factor : production of a clinical grade recombinant protein from Escherichia coli

The wide range of in vitro and in vivo activities of basic Fibroblast Growth Factor (bFGF) suggests that exogenous administration of this factor may be of great clinical interest in tissue repair processes. To address the study of bFGF as a therapeutical agent we have developed a recombinant DNA method for the production of human bFGF in Escherichia coli. Optimization of conditions for efficient expression and purification of the protein has yielded a clinical rhbFGF with full biological activity